Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hanno Glimm

Showing results (91-100 of 148) with videos related to

Pageof 15
Sort By:
Molecular Cancer Therapeutics|July 17, 2019
KIT-Dependent and KIT-Independent Genomic Heterogeneity of Resistance in Gastrointestinal Stromal Tumors - TORC1/2 Inhibition as Salvage StrategyThomas Mühlenberg, Julia Ketzer, Michael C Heinrich, et al.
Cancer Treatment and Research Communications|September 11, 2025
Rationale and design of the PAMSARC (pasireotide as maintenance treatment with monthly deep intramuscular injection in SSTR2/3/5-expressing synovial sarcoma and desmoplastic small round cell tumor) multicenter phase 2 trialChristoph E Heilig, Christoph Heining, Editha Gnutzmann, et al.
Cold Spring Harbor Molecular Case Studies|December 1, 2016
Integration of genomics and histology revises diagnosis and enables effective therapy of refractory cancer of unknown primary with <i>PDL1</i> amplificationStefan Gröschel, Martin Bommer, Barbara Hutter, et al.
NPJ Precision Oncology|June 17, 2026
Integration and validation of complementary ex vivo assays for functional precision oncologyAnna Loboda, Jasmina Paluncic, Micaela Freitas, et al.
EMBO Molecular Medicine|May 21, 2017
Succession of transiently active tumor-initiating cell clones in human pancreatic cancer xenograftsClaudia R Ball, Felix Oppel, Karl Roland Ehrenberg, et al.
Cold Spring Harbor Molecular Case Studies|March 6, 2019
Response to olaparib in a <i>PALB2</i> germline mutated prostate cancer and genetic events associated with resistancePeter Horak, Joachim Weischenfeldt, Gunhild von Amsberg, et al.
European Journal of Endocrinology|June 1, 2023
Outcome of immunotherapy in adrenocortical carcinoma: a retrospective cohort studyHanna Remde, Laura Schmidt-Pennington, Miriam Reuter, et al.
Cells|February 13, 2019
Systematic Generation of Patient-Derived Tumor Models in Pancreatic CancerKarl Roland Ehrenberg, Jianpeng Gao, Felix Oppel, et al.
The Journal of Clinical Endocrinology and Metabolism|June 22, 2019
Transcriptome Profiling of Adipose Tissue Reveals Depot-Specific Metabolic Alterations Among Patients with Colorectal CancerMariam Haffa, Andreana N Holowatyj, Mario Kratz, et al.
Oncogene|September 28, 2019
Identification and characterization of a BRAF fusion oncoprotein with retained autoinhibitory domainsFlorian Weinberg, Ricarda Griffin, Martina Fröhlich, et al.
Pageof 15

Showing results (91-100 of 148) with videos related to

Sort By:
Pageof 15
Molecular Cancer Therapeutics|July 17, 2019
KIT-Dependent and KIT-Independent Genomic Heterogeneity of Resistance in Gastrointestinal Stromal Tumors - TORC1/2 Inhibition as Salvage StrategyThomas Mühlenberg, Julia Ketzer, Michael C Heinrich, et al.
Cancer Treatment and Research Communications|September 11, 2025
Rationale and design of the PAMSARC (pasireotide as maintenance treatment with monthly deep intramuscular injection in SSTR2/3/5-expressing synovial sarcoma and desmoplastic small round cell tumor) multicenter phase 2 trialChristoph E Heilig, Christoph Heining, Editha Gnutzmann, et al.
Cold Spring Harbor Molecular Case Studies|December 1, 2016
Integration of genomics and histology revises diagnosis and enables effective therapy of refractory cancer of unknown primary with <i>PDL1</i> amplificationStefan Gröschel, Martin Bommer, Barbara Hutter, et al.
NPJ Precision Oncology|June 17, 2026
Integration and validation of complementary ex vivo assays for functional precision oncologyAnna Loboda, Jasmina Paluncic, Micaela Freitas, et al.
EMBO Molecular Medicine|May 21, 2017
Succession of transiently active tumor-initiating cell clones in human pancreatic cancer xenograftsClaudia R Ball, Felix Oppel, Karl Roland Ehrenberg, et al.
Cold Spring Harbor Molecular Case Studies|March 6, 2019
Response to olaparib in a <i>PALB2</i> germline mutated prostate cancer and genetic events associated with resistancePeter Horak, Joachim Weischenfeldt, Gunhild von Amsberg, et al.
European Journal of Endocrinology|June 1, 2023
Outcome of immunotherapy in adrenocortical carcinoma: a retrospective cohort studyHanna Remde, Laura Schmidt-Pennington, Miriam Reuter, et al.
Cells|February 13, 2019
Systematic Generation of Patient-Derived Tumor Models in Pancreatic CancerKarl Roland Ehrenberg, Jianpeng Gao, Felix Oppel, et al.
The Journal of Clinical Endocrinology and Metabolism|June 22, 2019
Transcriptome Profiling of Adipose Tissue Reveals Depot-Specific Metabolic Alterations Among Patients with Colorectal CancerMariam Haffa, Andreana N Holowatyj, Mario Kratz, et al.
Oncogene|September 28, 2019
Identification and characterization of a BRAF fusion oncoprotein with retained autoinhibitory domainsFlorian Weinberg, Ricarda Griffin, Martina Fröhlich, et al.
Pageof 15